Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

(2017) Sani H. Kizilbash et al.   MOLECULAR CANCER THERAPEUTICS

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA

(2017) Tovah A. Day et al.   Nature Communications

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

(2017) Johann de Bono et al.   Cancer Discovery

Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies

(2017) Paul Lesueur et al.   Oncotarget

Translational research in radiobiology in the framework of France HADRON national collaboration

(2017) Claire Rodriguez-Lafrasse et al.   Translational Cancer Research

A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma

(2016) Elias A. El-Habr et al.   ACTA NEUROPATHOLOGICA

The anti‐hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ‐dependent inhibition of the AKT pathway

(2016) Suzana Assad Kahn et al.   EMBO Molecular Medicine

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors

(2016) Ann-Gerd Thorsell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dosimetry for radiobiology experiments at GANIL

(2016) Florent Durantel et al.   NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT

Cellular and molecular portrait of eleven human glioblastoma cell lines under photon and carbon ion irradiation

(2015) S. Ferrandon et al.   CANCER LETTERS

Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells

(2015) S. U. Ahmed et al.   CANCER RESEARCH

Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent

(2015) Bing Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Carbon-ion beams effectively induce growth inhibition and apoptosis in human neural stem cells compared with glioblastoma A172 cells

(2015) Mayu Isono et al.   JOURNAL OF RADIATION RESEARCH

Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience

(2015) Tadashi Kamada et al.   LANCET ONCOLOGY

Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data

(2014) Valentina Boeva et al.   BIOINFORMATICS

Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3

(2014) Carole Beck et al.   EXPERIMENTAL CELL RESEARCH

BRG1 promotes the repair of DNA double-strand breaks by facilitating the replacement of RPA with RAD51

(2014) W. Qi et al.   JOURNAL OF CELL SCIENCE

The epidemiology of glioma in adults: a "state of the science" review

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways

(2014) Carole Beck et al.   NUCLEIC ACIDS RESEARCH

A Monte Carlo study for the calculation of the average linear energy transfer (LET) distributions for a clinical proton beam line and a radiobiological carbon ion beam line

(2014) F Romano et al.   PHYSICS IN MEDICINE AND BIOLOGY

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells

(2013) M Venere et al.   CELL DEATH AND DIFFERENTIATION

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

(2013) Nigel Bundred et al.   INVESTIGATIONAL NEW DRUGS

The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair

(2013) Amanda L. Fenton et al.   NUCLEIC ACIDS RESEARCH

Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: Explorative hypothesis-generating retrospective analysis

(2013) Stephanie E. Combs et al.   RADIOTHERAPY AND ONCOLOGY

Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation

(2012) Takahisa Hirai et al.   CANCER SCIENCE

LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets

(2012) Andreas Wilm et al.   NUCLEIC ACIDS RESEARCH

Repair of DNA damage induced by accelerated heavy ions-A mini review

(2011) Ryuichi Okayasu   INTERNATIONAL JOURNAL OF CANCER

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

(2011) Stephanie E Combs et al.   Radiation Oncology

CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors

(2010) Cristina Patru et al.   BMC CANCER

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide

(2010) Giuseppe Minniti et al.   RADIOTHERAPY AND ONCOLOGY

The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation

(2009) J. Portnow et al.   CLINICAL CANCER RESEARCH

ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays

(2009) Yifang Hu et al.   JOURNAL OF IMMUNOLOGICAL METHODS

A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients

(2008) L. Rosso et al.   CANCER RESEARCH

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential

(2008) Fiona A. Dungey et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS